AACR: Anti-PI3K/MEK Inhibitor Targeted Therapy Combo Shows Activity

A new agent, SAR245409, that simultaneous targets two pathways important for the growth of tumors--the PI3K/mTOR pathway and the MAPK pathway--has shown activity in advanced solid tumors, according to results from a phase I trial presented at the American Association for Cancer Research Annual Meeting.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news